Teprotumumab for the Treatment of Active Thyroid Eye Disease | Zendy

Raymond S. Douglas | Zendy; George J. Kahaly | Zendy; Amy Patel | Zendy; Saba Sile | Zendy; Elizabeth H. Thompson | Zendy; Renee Perdok | Zendy; James C. Fleming | Zendy; Brian Fowler | Zendy; Claudio Marcocci | Zendy; Michele Marinò | Zendy; Alessandro Antonelli | Zendy; Roger A. Dailey | Zendy; Gerald J. Harris | Zendy; Anja Eckstein | Zendy; Jade S. Schiffman | Zendy; Rosa A. Tang | Zendy; Christine C. Nelson | Zendy; Mario Salvi | Zendy; Sara T. Wester | Zendy; Jeffrey W. Sherman | Zendy; Thomas Vescio | Zendy; Robert J. Holt | Zendy; Terry J. Smith | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Teprotumumab for the Treatment of Active Thyroid Eye Disease

Author(s) -

Raymond S. Douglas,

George J. Kahaly,

Amy Patel,

Saba Sile,

Elizabeth H. Thompson,

Renee Perdok,

James C. Fleming,

Brian Fowler,

Claudio Marcocci,

Michele Marinò,

Alessandro Antonelli,

Roger A. Dailey,

Gerald J. Harris,

Anja Eckstein,

Jade S. Schiffman,

Rosa A. Tang,

Christine C. Nelson,

Mario Salvi,

Sara T. Wester,

Jeffrey W. Sherman,

Thomas Vescio,

Robert J. Holt,

Terry J. Smith

Publication year - 2020

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1910434

Subject(s) - blinding , medicine , food and drug administration , pathogenesis , disease , thyroid , thyroid disease , eye disease , bioinformatics , ophthalmology , pharmacology , biology , clinical trial

Thyroid eye disease is a debilitating, disfiguring, and potentially blinding periocular condition for which no Food and Drug Administration-approved medical therapy is available. Strong evidence has implicated the insulin-like growth factor I receptor (IGF-IR) in the pathogenesis of this disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research